JOHNS HOPKINS MEDICINE
|
BRAIN SCIENCE INSTITUTE
DRUG DISCOVERY IN ACADEMIA THE NEW PARADIGM FOR DRUG DISCOVERY
OCTOBER 18, 2011 B A LT I M O R E C O N V E N T I O N C E N T E R The business of drug discovery is changing. Over the last several years a new model has emerged bridging academic translational strengths with the pharmaceutical and biotechnology industries. What are the opportunities, challenges and risks to be addressed to forge these alliances? What are best practices? What could this new future look like?
KEYNOTE: “ACADEMIC TRANSLATIONAL CENTERS: A NEW PARADIGM FOR EARLY STAGE DRUG DISCOVERY" Steven M. Paul, M.D. Weill Cornell Medical College of Cornell University DRUG DISCOVERY CENTER PRESENTATIONS: University of California San Francisco The Centre for Drug Research and Development, Canada Harvard University • Johns Hopkins University University of North Carolina • Vanderbilt University EARLY STAGE DRUG DISCOVERY & PARTNERING WITH ACADEMIA: PHARMA'S PERSPECTIVE: Merck • Eisai • Astra Zeneca • Johnson and Johnson • Pfizer FUNDING DRUG DISCOVERY CENTERS: National Institutes of Health • Maryland Biotechnology Center New Enterprise Associates • Cure Huntington Disease Initiative Prostate Cancer Foundation SUCCESSES, CHALLENGES, OPPORTUNITIES FOR DRUG DISCOVERY CENTERS STRUCTURING PARTNERSHIP PROGRAMS: A VIEW FROM ACADEMIA & INDUSTRY POSTER SESSION AND PARTNERING MEETINGS
FOR MORE INFORMATION & REGISTRATION: http://www.brainscienceinstitute.org/index.php/news/ upcoming_events/drug_discovery_in_academia/
OR CONTACT: Aditya Polsani •
[email protected] • 410-353-3470 Barbara Slusher •
[email protected] • 410-614-0662
